Nifty
:
23349.90
Sensex
:
77155.79
-168.60 (-0.72%)
-422.59 (-0.54%)
Nifty
Sensex
:
:
23349.90
77155.79
-168.60 (-0.72%)
-422.59 (-0.54%)

Glenmark Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

Rating :
N/A

BSE: 532296 | NSE: GLENMARK

NSE BSE
1338.15
05-Jul-2024
  • Open
  • High
  • Low
  • Previous Close
  •  1295.00
  •  1356.50
  •  1291.30
  •  1295.50
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1454791
  •  19458.93
  •  1830.95
  •  761.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 42,112.35
  • N/A
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 41,853.76
  • 0.17%
  • 4.98

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.65%
  • 2.26%
  • 13.60%
  • FII
  • DII
  • Others
  • 23.05%
  • 12.15%
  • 2.29%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.87
  • 2.11
  • -1.35

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -0.16
  • -6.78
  • -12.42

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.76
  • 30.71
  • 37.27

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 14.69
  • 13.99
  • 12.71

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.70
  • 2.23
  • 2.39

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 10.38
  • 9.74
  • 10.62

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Net Sales
3,433.80
3,207.38
7.06%
3,244.19
3,036.07
6.85%
3,062.95
3,000.51
2.08%
2,506.70
3,100.18
-19.14%
Expenses
2,831.88
2,745.09
3.16%
2,655.97
2,598.71
2.20%
2,558.61
2,602.60
-1.69%
2,715.35
2,626.14
3.40%
EBITDA
601.91
462.28
30.20%
588.21
437.35
34.49%
504.34
397.91
26.75%
-208.65
474.04
-
EBIDTM
17.53%
14.41%
18.13%
14.41%
16.47%
13.26%
-8.32%
15.29%
Other Income
39.42
1.70
2,218.82%
31.49
19.72
59.69%
773.16
-42.42
-
45.41
70.56
-35.64%
Interest
48.48
121.46
-60.09%
39.58
111.61
-64.54%
148.56
109.14
36.12%
134.34
97.11
38.34%
Depreciation
120.28
141.45
-14.97%
117.79
142.04
-17.07%
151.34
135.02
12.09%
147.07
151.51
-2.93%
PBT
472.57
-124.35
-
462.33
151.40
205.37%
530.83
-688.40
-
-521.38
329.86
-
Tax
118.09
55.95
111.06%
122.10
113.72
7.37%
1,769.47
-138.90
-
-71.80
144.09
-
PAT
354.49
-180.30
-
340.24
37.68
802.97%
-1,238.65
-549.49
-
-449.58
185.77
-
PATM
10.32%
-5.62%
10.49%
1.24%
-40.44%
-18.31%
-17.94%
5.99%
EPS
12.55
-2.90
-
12.06
5.31
127.12%
-43.17
-15.18
-
-12.45
9.66
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
12,247.64
11,813.10
11,583.24
12,304.90
10,943.93
10,640.97
9,865.47
9,074.42
9,079.41
7,561.67
6,680.94
Net Sales Growth
-0.78%
1.98%
-5.86%
12.44%
2.85%
7.86%
8.72%
-0.05%
20.07%
13.18%
 
Cost Of Goods Sold
4,207.95
4,352.00
4,204.38
4,312.08
3,620.18
3,623.78
3,283.71
2,963.32
2,552.03
2,246.58
1,538.25
Gross Profit
8,039.69
7,461.10
7,378.85
7,992.82
7,323.75
7,017.18
6,581.76
6,111.10
6,527.39
5,315.09
5,142.69
GP Margin
65.64%
63.16%
63.70%
64.96%
66.92%
65.94%
66.72%
67.34%
71.89%
70.29%
76.98%
Total Expenditure
10,761.81
10,617.77
9,948.23
9,984.60
8,859.55
8,942.89
8,279.67
7,459.05
7,042.71
6,124.52
5,466.62
Power & Fuel Cost
-
124.00
111.75
200.64
164.67
173.69
165.25
137.47
127.02
120.47
109.11
% Of Sales
-
1.05%
0.96%
1.63%
1.50%
1.63%
1.68%
1.51%
1.40%
1.59%
1.63%
Employee Cost
-
2,868.14
2,600.78
2,447.42
2,343.71
2,254.78
2,056.07
1,871.84
1,640.81
1,378.19
1,212.61
% Of Sales
-
24.28%
22.45%
19.89%
21.42%
21.19%
20.84%
20.63%
18.07%
18.23%
18.15%
Manufacturing Exp.
-
813.30
633.51
784.63
638.74
669.50
725.16
648.59
546.75
956.59
1,323.66
% Of Sales
-
6.88%
5.47%
6.38%
5.84%
6.29%
7.35%
7.15%
6.02%
12.65%
19.81%
General & Admin Exp.
-
1,313.59
1,212.13
1,264.86
1,027.60
1,168.32
891.10
526.29
1,022.89
491.20
253.29
% Of Sales
-
11.12%
10.46%
10.28%
9.39%
10.98%
9.03%
5.80%
11.27%
6.50%
3.79%
Selling & Distn. Exp.
-
1,092.27
1,137.20
896.31
943.21
1,005.63
1,125.08
996.99
1,064.70
892.67
991.23
% Of Sales
-
9.25%
9.82%
7.28%
8.62%
9.45%
11.40%
10.99%
11.73%
11.81%
14.84%
Miscellaneous Exp.
-
54.46
48.49
78.68
121.44
47.19
33.29
314.55
88.52
38.82
991.23
% Of Sales
-
0.46%
0.42%
0.64%
1.11%
0.44%
0.34%
3.47%
0.97%
0.51%
0.58%
EBITDA
1,485.81
1,195.33
1,635.01
2,320.30
2,084.38
1,698.08
1,585.80
1,615.37
2,036.70
1,437.15
1,214.32
EBITDA Margin
12.13%
10.12%
14.12%
18.86%
19.05%
15.96%
16.07%
17.80%
22.43%
19.01%
18.18%
Other Income
889.48
839.99
288.90
166.67
50.22
159.60
208.14
91.40
37.37
20.00
6.88
Interest
370.96
515.97
349.04
298.10
353.11
377.32
334.58
285.57
237.32
178.88
190.15
Depreciation
536.48
581.91
569.17
486.71
443.55
417.17
325.90
301.88
264.37
234.28
300.41
PBT
944.35
937.45
1,005.70
1,702.16
1,337.93
1,063.20
1,133.45
1,119.33
1,572.38
1,043.98
730.63
Tax
1,937.86
1,867.35
329.40
447.60
412.39
320.11
375.64
315.46
382.68
300.94
334.07
Tax Rate
205.21%
5117.43%
137.34%
31.06%
29.83%
29.20%
28.88%
28.18%
25.66%
28.83%
61.46%
PAT
-993.50
-1,899.00
-169.72
941.71
970.04
775.97
924.98
803.78
1,108.80
743.23
209.54
PAT before Minority Interest
-1,018.31
-1,830.85
-89.56
993.65
970.09
775.97
924.99
803.87
1,108.75
743.04
209.47
Minority Interest
-24.81
-68.15
-80.16
-51.94
-0.05
0.00
-0.01
-0.09
0.05
0.19
0.07
PAT Margin
-8.11%
-16.08%
-1.47%
7.65%
8.86%
7.29%
9.38%
8.86%
12.21%
9.83%
3.14%
PAT Growth
0.00%
-
-
-2.92%
25.01%
-16.11%
15.08%
-27.51%
49.19%
254.70%
 
EPS
-35.21
-67.29
-6.01
33.37
34.37
27.50
32.78
28.48
39.29
26.34
7.43

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
7,847.93
9,473.92
9,086.65
7,064.63
6,070.51
5,605.18
5,163.48
4,492.52
3,629.64
1,783.49
Share Capital
28.22
28.22
28.22
28.22
28.22
28.22
28.22
28.22
28.22
27.13
Total Reserves
7,801.48
9,428.09
9,042.13
7,014.78
6,028.59
5,566.35
5,124.75
4,462.86
3,599.98
1,756.36
Non-Current Liabilities
-357.23
2,621.45
1,269.61
2,803.62
3,033.01
2,279.94
2,824.12
3,257.81
1,499.40
2,749.09
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Unsecured Loans
0.00
3,852.14
2,571.74
3,888.82
4,042.99
3,573.75
4,141.78
4,536.34
2,487.30
2,574.38
Long Term Provisions
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Liabilities
5,818.59
4,546.24
4,689.43
4,201.02
4,125.98
4,021.09
3,287.89
2,702.68
3,999.25
3,776.71
Trade Payables
2,535.93
2,000.43
2,288.66
2,237.77
2,125.84
2,220.75
1,869.78
1,743.22
1,940.79
1,948.04
Other Current Liabilities
1,517.23
1,605.31
1,446.27
885.78
1,001.63
1,013.21
690.60
509.32
1,137.01
1,264.30
Short Term Borrowings
833.36
350.00
370.00
513.01
442.60
303.02
295.04
187.19
787.42
347.60
Short Term Provisions
932.08
590.51
584.50
564.45
555.91
484.11
432.46
262.95
134.03
216.78
Total Liabilities
13,308.91
17,006.95
15,397.16
14,068.92
13,229.11
11,905.83
11,275.12
10,452.59
9,127.99
8,309.10
Net Block
4,210.16
5,421.76
5,887.25
5,128.85
5,028.56
3,670.25
3,029.55
2,755.09
2,593.55
2,015.38
Gross Block
9,619.64
10,359.59
10,213.47
8,731.58
8,269.83
6,527.27
5,367.95
4,769.92
4,300.54
3,495.47
Accumulated Depreciation
5,409.48
4,937.83
4,326.23
3,602.73
3,241.28
2,857.01
2,338.39
2,014.83
1,706.99
1,480.09
Non Current Assets
5,880.82
6,840.24
7,114.82
6,709.33
6,425.49
5,209.02
4,286.43
3,577.96
3,223.69
2,978.04
Capital Work in Progress
661.88
1,189.64
1,009.87
1,381.67
1,221.89
1,398.94
1,121.87
708.11
542.79
477.13
Non Current Investment
789.66
44.57
49.62
24.63
24.59
29.66
14.66
15.69
17.20
17.12
Long Term Loans & Adv.
211.70
180.80
161.38
146.29
123.97
94.36
119.78
98.94
69.99
468.16
Other Non Current Assets
7.42
3.46
6.70
27.89
26.49
15.80
0.56
0.13
0.16
0.27
Current Assets
7,428.08
8,423.64
8,282.35
7,359.58
6,803.62
6,696.82
6,988.69
6,874.64
5,904.30
5,331.06
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
2,513.05
2,373.62
2,499.83
2,276.83
2,135.62
2,252.07
2,030.59
2,139.05
1,567.76
1,269.04
Sundry Debtors
1,858.41
3,665.17
3,101.14
2,572.05
2,408.96
2,194.59
2,331.81
2,404.32
2,492.65
2,511.76
Cash & Bank
1,659.46
1,160.30
1,411.52
1,139.16
1,111.24
937.76
1,234.69
1,057.66
857.12
775.88
Other Current Assets
1,397.16
316.61
297.46
671.05
1,147.78
1,312.40
1,391.61
1,273.61
986.77
774.38
Short Term Loans & Adv.
1,218.95
907.93
972.41
700.49
544.48
547.18
580.83
590.22
594.89
742.94
Net Current Assets
1,609.49
3,877.39
3,592.92
3,158.56
2,677.63
2,675.73
3,700.80
4,171.96
1,905.05
1,554.35
Total Assets
13,308.90
15,263.88
15,397.17
14,068.91
13,229.11
11,905.84
11,275.12
10,452.60
9,127.99
8,309.10

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
-265.44
625.39
1,108.65
1,131.21
1,392.41
1,324.17
1,648.05
657.43
344.85
481.68
PBT
569.19
868.45
1,441.25
1,382.47
1,096.08
1,300.63
1,119.33
1,491.43
1,043.98
543.54
Adjustment
1,009.81
1,471.96
787.11
644.82
636.23
329.83
571.28
726.56
391.03
522.76
Changes in Working Capital
-796.95
-1,074.48
-561.26
-385.84
127.06
136.34
309.06
-861.51
-611.96
-266.82
Cash after chg. in Working capital
782.05
1,265.93
1,667.09
1,641.45
1,859.37
1,766.81
1,999.67
1,356.48
823.05
799.49
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,047.49
-640.54
-558.44
-510.24
-466.95
-442.63
-351.61
-699.05
-478.20
-317.81
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
4,560.89
-528.49
-333.28
-675.24
-783.52
-698.99
-1,013.34
-712.35
-880.17
-540.04
Net Fixed Assets
-234.42
-220.67
-155.36
-184.89
-248.78
455.14
-362.24
-256.09
-286.93
-1,354.84
Net Investments
-2,632.08
-1,773.32
-1,569.44
-2,276.02
-1,445.18
-56.07
-1,345.98
-8.28
-198.90
-250.28
Others
7,427.39
1,465.50
1,391.52
1,785.67
910.44
-1,098.06
694.88
-447.98
-394.34
1,065.08
Cash from Financing Activity
-3,906.13
-77.46
-520.49
-441.78
-444.66
-738.74
-468.50
543.15
698.60
199.22
Net Cash Inflow / Outflow
389.32
19.45
254.88
14.20
164.23
-113.56
166.21
488.24
163.27
140.86
Opening Cash & Equivalents
1,443.03
1,410.53
1,138.10
1,110.28
936.28
1,233.36
1,056.36
857.12
763.74
794.80
Closing Cash & Equivalent
1,658.27
1,443.03
1,410.53
1,138.10
1,110.28
936.28
1,233.36
1,056.36
857.12
763.74

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
277.46
335.13
321.45
249.60
214.65
198.27
182.62
159.16
128.59
65.74
ROA
-11.86%
-0.54%
6.74%
7.11%
6.17%
7.98%
7.40%
11.33%
8.52%
2.58%
ROE
-21.18%
-0.97%
12.33%
14.81%
13.32%
17.21%
16.67%
27.31%
27.46%
8.79%
ROCE
4.88%
4.43%
14.19%
15.30%
14.04%
16.47%
14.77%
20.54%
18.53%
12.40%
Fixed Asset Turnover
2.77
2.74
2.94
2.97
1.44
1.66
1.80
2.03
1.96
1.90
Receivable days
36.38
43.76
37.24
36.01
78.95
83.73
94.95
97.29
119.39
125.97
Inventory Days
32.19
31.52
31.35
31.90
75.25
79.22
83.59
73.65
67.68
59.42
Payable days
190.23
186.18
191.57
219.98
98.44
97.43
96.28
101.59
117.03
95.22
Cash Conversion Cycle
-121.67
-110.90
-122.98
-152.06
55.77
65.53
82.26
69.35
70.04
90.17
Total Debt/Equity
0.13
0.46
0.40
0.67
0.80
0.80
0.90
1.05
1.10
2.13
Interest Cover
1.07
1.69
5.83
4.92
3.90
4.89
4.92
7.28
6.84
3.86

Annual Reports:

FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015

News Update:


  • Glenmark Pharma - Quarterly Results
    14th Nov 2024, 18:37 PM

    Read More
  • Glenmark’s US arm recalls bottles of Ryaltris Nasal Spray
    14th Oct 2024, 12:45 PM

    Additionally, Glenmark Pharmaceuticals Inc, US, is also recalling 11,568 tubes of Ciclopirox Gel

    Read More
  • USFDA completes GMP inspection at Glenmark Pharma’s facility at Aurangabad
    21st Sep 2024, 16:01 PM

    The inspection closed with no observation

    Read More
  • Glenmark’s US arm recalling bottles of Indomethacin Extended-Release Capsules
    27th Aug 2024, 12:48 PM

    Glenmark Pharmaceuticals Inc, USA initiated the Class II recall on July 31

    Read More
  • Glenmark Pharmaceuticals’ arm launches Olopatadine Hydrochloride Ophthalmic Solution
    19th Aug 2024, 09:44 AM

    For the latest 52 weeks’ period ending July 13, 2024, the Pataday Twice Daily Relief (OTC) market achieved annual sales of approximately $26.4 million

    Read More
  • Glenmark Pharmaceuticals reports 9-fold jump in Q1 consolidated net profit
    16th Aug 2024, 14:30 PM

    Total consolidated income of the company increased by 7.20% at Rs 3275.68 crore for Q1FY25

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.